Tumor-associated macrophages in pediatric classical Hodgkin lymphoma: Association with Epstein-Barr virus, lymphocyte subsets, and prognostic impact

Clinical Cancer Research

Volumn 18, Issue 14, 2012, Pages 3762-3771

  Barros, Mário Henrique M ^a   Hassan, Rocio ^b   Niedobitek, Gerald ^a  

^a Institute for Pathology   (Germany)

^b INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CD163 ANTIGEN; CD68 ANTIGEN; CD83 ANTIGEN; GRANZYME B; LANGERIN;

ADOLESCENT; ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CELL COMPOSITION; CHILD; CLASSICAL HODGKIN LYMPHOMA; CONTROLLED STUDY; DENDRITIC CELL; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; MACROPHAGE FUNCTION; MAJOR CLINICAL STUDY; NODULAR SCLEROSIS HODGKIN LYMPHOMA; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SCHOOL CHILD; SURVIVAL TIME; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

ADOLESCENT; ADULT; CHILD; DENDRITIC CELLS; DISEASE-FREE SURVIVAL; FEMALE; HERPESVIRUS 4, HUMAN; HODGKIN DISEASE; HUMANS; LYMPHOCYTE SUBSETS; MACROPHAGES; MALE; PROGNOSIS; TISSUE ARRAY ANALYSIS; TUMOR MICROENVIRONMENT;

EID: 84863888424     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0129     Document Type: Article

References (44)

1. Aldinucci D, Gloghini A, Pinto A, De Filippi R, Carbone A. The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. J Pathol 2010;221:248-63.
2. Barros MH, Vera-Lozada G, Soares FA, Niedobitek G, Hassan R. Tumor microenvironment composition in pediatric classical hodgkin lymphoma is modulated by age and epstein-barr virus infection. Int J Cancer. 2011 Oct 25. [Epub ahead of print].
3. Barros MH, Hassan R, Niedobitek G. Disease patterns in pediatric classical Hodgkin lymphoma: a report from a developing area in Brazil. Hematol Oncol 2011;29:190-5.
4. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010;362:875-85.
5. Kamper P, Bendix K, Hamilton-Dutoit S, Honore B, Nyengaard JR, d'Amore F. Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma. Haematologica 2011;96:269-76.
6. Tzankov A, Matter MS, Dirnhofer S. Refined prognostic role of CD68-positive tumor macrophages in the context of the cellular micromilieu of classical Hodgkin lymphoma. Pathobiology 2010;77:301-8.
7. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010;22:231-7.
8. Jaiswal S, Chao MP, Majeti R, Weissman IL. Macrophages as mediators of tumor immunosurveillance. Trends Immunol 2010;31:212-9.
9. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity 2010;32:593-604.
10. Moser M, Murphy KM. Dendritic cell regulation of TH1-TH2 development. Nat Immunol 2000;1:199-205.
11. Steinman RM, Hawiger D, Liu K, Bonifaz L, Bonnyay D, Mahnke K, et al. Dendritic cell function in vivo during the steady state: a role in peripheral tolerance. Ann N Y Acad Sci 2003;987:15-25. (Pubitemid 36584003)
12. Banchereau J, Paczesny S, Blanco P, Bennett L, Pascual V, Fay J, et al. Dendritic cells: controllers of the immune system and a new promise for immunotherapy. Ann N Y Acad Sci 2003;987:180-7. (Pubitemid 36584021)
13. Gilliet M, Liu YJ. Human plasmacytoid-derived dendritic cells and the induction of T-regulatory cells. Hum Immunol 2002;63:1149-55. (Pubitemid 36025989)
14. Wakkach A, Fournier N, Brun V, Breittmayer JP, Cottrez F, Groux H. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity 2003;18:605-17. (Pubitemid 36588578)
15. Murphy K, Travers P, Walport M, Janeway C. Janeway's immunobiology. 7th ed. New York: Garland Science; 2008.
16. Chaplin DD. Overview of the immune response. J Allergy Clin Immunol 2010;125:S3-23.
17. Faria AM, de Moraes SM, de Freitas LH, Speziali E, Soares TF, Figueiredo-Neves SP, et al. Variation rhythms of lymphocyte subsets during healthy aging. Neuroimmunomodulation 2008;15:365-79.
18. Bartlett JA, Goldklang AR, Schleifer SJ, Keller SE. Immune function in healthy inner-city children. Clin Diagn Lab Immunol 2001;8:740-6. (Pubitemid 32613700)
19. Luebke RW, Chen DH, Dietert R, Yang Y, Luster MI. Immune system maturity and sensitivity to chemical exposure. J Toxicol Environ Health, Part A: Current Issues 2006;69:811-25.
20. Erkeller-Yuksel FM, Deneys V, Yuksel B, Hannet I, Hulstaert F, Hamilton C, et al. Age-related changes in human blood lymphocyte subpopulations. J Pediatr 1992;120:216-22.
21. Heldrup J, Kalm O, Prellner K. Blood T and B lymphocyte subpopulations in healthy infants and children. Acta Paediatr 1992;81:125-32.
22. Swerdlow SHInternational Agency for Research on Cancer. World Health Organization.WHOclassification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: International Agency for Research on Cancer; 2008.
23. Barros MH, Scheliga A, De Matteo E, Minnicelli C, Soares FA, Zalcberg IR, et al. Cell cycle characteristics and Epstein-Barr virus are differentially associated with aggressive and non-aggressive subsets of Hodgkin lymphoma in pediatric patients. Leuk Lymphoma 2010;51:1513-22.
24. Chetaille B, Bertucci F, Finetti P, Esterni B, Stamatoullas A, Picquenot JM, et al. Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood 2009;113:2765-3775.
25. Frisan T, Sjoberg J, Dolcetti R, Boiocchi M, De Re V, Carbone A, et al. Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease. Blood 1995;86:1493-501.
26. Vakkila J, Lotze MT, Riga C, Jaffe R. A basis for distinguishing cultured dendritic cells and macrophages in cytospins and fixed sections. Pediatr Dev Pathol 2005;8:43-51. (Pubitemid 40568919)
27. Steidl C, Farinha P, Gascoyne RD. Macrophages predict treatment outcome in Hodgkin's lymphoma. Haematologica 2011;96:186-9.
28. Turvey SE, Broide DH. Innate immunity. J Allergy Clin Immunol 2010;125:S24-32.
29. Ohri CM, Shikotra A, Green RH, Waller DA, Bradding P. Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur Respir J 2009;33:118-26.
30. Pettersen JS, Fuentes-Duculan J, Suarez-Farinas M, Pierson KC, Pitts-Kiefer A, Fan L, et al. Tumor-associated macrophages in the cutaneous SCC microenvironment are heterogeneously activated. J Invest Dermatol 2011;131:1322-30.
31. Zaki MA, Wada N, Ikeda J, Shibayama H, Hashimoto K, Yamagami T, et al. Prognostic implication of types of tumor-associated macrophages in Hodgkin lymphoma. Virchows Arch 2011;459:361-6.
32. Jakovic LR, Mihaljevic BS, Perunicic Jovanovic MD, Bogdanovic AD, Andjelic BM, Bumbasirevic VZ. The prognostic relevance of tumor associated macrophages in advanced stage classical Hodgkin lymphoma. Leuk Lymphoma 2011;52:1913-9.
33. Azambuja D, Natkunam Y, Biasoli I, Lossos IS, Anderson MW, Morais JC, et al. Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma. Ann Oncol 2012;23:736-42.
34. Gottfried E, Kunz-Schughart LA, Weber A, Rehli M, Peuker A, Muller A, et al. Expression of CD68 in non-myeloid cell types. Scand J Immunol 2008;67:453-63. (Pubitemid 351519391)
35. Leong ASY, Cooper K, Leong FJWM. Manual of diagnostic antibodies for immunohistology. 2nd ed. London: Greenwich Medical Media; 2003.
36. Zhou LJ, Tedder TF. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. J Immunol 1995;154:3821-35.
37. Mengshol JA, Golden-Mason L, Castelblanco N, Im KA, Dillon SM, Wilson CC, et al. Impaired plasmacytoid dendritic cell maturation and differential chemotaxis in chronic hepatitis C virus: associations with antiviral treatment outcomes. Gut 2009;58:964-73.
38. Ishigami S, Natsugoe S, Matsumoto M, Okumura H, Sakita H, Nakashima S, et al. Clinical implications of intratumoral dendritic cell infiltration in esophageal squamous cell carcinoma. Oncol Rep 2003;10:1237-40.
39. Inoshima N, Nakanishi Y, Minami T, Izumi M, Takayama K, Yoshino I, et al. The influence of dendritic cell infiltration and vascular endothelial growth factor expression on the prognosis of non-small cell lung cancer. Clin Cancer Res 2002;8:3480-6. (Pubitemid 35340725)
40. Treilleux I, Blay JY, Bendriss-Vermare N, Ray-Coquard I, Bachelot T, Guastalla JP, et al. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res 2004;10:7466-74. (Pubitemid 39561754)
41. Vakkila J, Thomson AW, Vettenranta K, Sariola H, Saarinen-Pihkala UM. Dendritic cell subsets in childhood and in children with cancer: relation to age and disease prognosis. Clin Exp Immunol 2004;135:455-61. (Pubitemid 38297146)
42. Labidi-Galy SI, Sisirak V, Meeus P, Gobert M, Treilleux I, Bajard A, et al. Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. Cancer Res 2011;71:5423-34.
43. Sholl LM, Hornick JL, Pinkus JL, Pinkus GS, Padera RF. Immunohistochemical analysis of langerin in langerhans cell histiocytosis and pulmonary inflammatory and infectious diseases. Am J Surg Pathol 2007;31:947-52. (Pubitemid 47165150)
44. Braz-Silva PH, Vitale S, Butori C, Guevara N, Santini J, Magalhaes M, et al. Specific infiltration of langerin-positive dendritic cells in EBV-infected tonsil, Hodgkin lymphoma and nasopharyngeal carcinoma. Int J Cancer 2011;128:2501-8.